Suchergebnisse - "Wang, Shining"

PubPharm (45)

1

CD38-BINDING FUSION PROTEIN COMBINATION THERAPY

enthalten in: Europäisches Patentamt | 2024

von COLLINS SABRINA | PAROT XAVIER | LI SHUANG | +6

2

CD38-BINDING FUSION PROTEIN COMBINATION THERAPY

enthalten in: Europäisches Patentamt | 2024

von POGUE SARAH | COLLINS SABRINA | PAROT XAVIER | +8

3

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

enthalten in: Cancer medicine | 2024

von Juric, D. | Barve, M. | Vaishampayan, U. | +19

4

Origin and stability of pit lake water in Baiyinhua, Inner Mongolia, based on hydrochemistry and stable isotopes

enthalten in: Isotopes in environmental and health studies | 2024

von Pei, S. | Zhang, D. | Wang, S. | +1

5

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

enthalten in: Cancer Medicine | 2024

von Juric, D. | Barve, M. | Vaishampayan, U. | +19

6

Clinical Characterization of [18F]T-008, a Cholesterol 24-Hydroxylase PET Ligand : Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2023

von Constantinescu, C. | Brown, T. | Wang, S. | +4

7

DOSING OF CD38-BINDING FUSION PROTEIN

enthalten in: Europäisches Patentamt | 2023

von COLLINS SABRINA | PAROT XAVIER | LI SHUANG | +8

8

The correlation between Th17/Treg immune dysregulation and the disease severity in chronic spontaneous urticaria patients

enthalten in: Immunity, inflammation and disease | 2023

von Yang, X. | Chen, L. | Wang, S. | +3

9

Correction to : A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Kim, R. | Leal, A. | Parikh, A. | +9

ErratumFor: Cancer Chemother Pharmacol. 2023 Apr;91(4):291-300. - PMID 36738333

10

A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Kim, R. | Leal, A. | Parikh, A. | +9

ErratumIn: Cancer Chemother Pharmacol. 2023 Mar 26;:. - PMID 36967405

1
2
3
4
5
Nächster »
[5]